228 related articles for article (PubMed ID: 29760048)
21. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
22. Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by Hras
Jolly LA; Massoll N; Franco AT
J Clin Cell Immunol; 2016 Oct; 7(5):. PubMed ID: 27942419
[TBL] [Abstract][Full Text] [Related]
23. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
24. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
25. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.
Tsumagari K; Abd Elmageed ZY; Sholl AB; Friedlander P; Abdraboh M; Xing M; Boulares AH; Kandil E
Cancer Lett; 2015 Nov; 368(1):46-53. PubMed ID: 26208433
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
28. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
[TBL] [Abstract][Full Text] [Related]
30. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
[TBL] [Abstract][Full Text] [Related]
31. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
32. KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas.
Tampakis A; Tampaki EC; Posabella A; Zettl A; Kouraklis G; von Flüe M; Guenin MO
Pancreas; 2017 Jan; 46(1):e5-e7. PubMed ID: 27977634
[No Abstract] [Full Text] [Related]
33. Transposon mutagenesis identifies chromatin modifiers cooperating with
Montero-Conde C; Leandro-Garcia LJ; Chen X; Oler G; Ruiz-Llorente S; Ryder M; Landa I; Sanchez-Vega F; La K; Ghossein RA; Bajorin DF; Knauf JA; Riordan JD; Dupuy AJ; Fagin JA
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):E4951-E4960. PubMed ID: 28584132
[TBL] [Abstract][Full Text] [Related]
34. Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Jagadeeshan S; Prasad M; Badarni M; Ben-Lulu T; Liju VB; Mathukkada S; Saunders C; Shnerb AB; Zorea J; Yegodayev KM; Wainer M; Vtorov L; Allon I; Cohen O; Gausdal G; Friedmann-Morvinski D; Cheong SC; Ho AL; Rosenberg AJ; Kessler L; Burrows F; Kong D; Grandis JR; Gutkind JS; Elkabets M
Cancer Res; 2023 Apr; 83(7):1031-1047. PubMed ID: 36753744
[TBL] [Abstract][Full Text] [Related]
35. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
36.
Krishnamoorthy GP; Davidson NR; Leach SD; Zhao Z; Lowe SW; Lee G; Landa I; Nagarajah J; Saqcena M; Singh K; Wendel HG; Dogan S; Tamarapu PP; Blenis J; Ghossein RA; Knauf JA; Rätsch G; Fagin JA
Cancer Discov; 2019 Feb; 9(2):264-281. PubMed ID: 30305285
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
39. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
40. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]